866-997-4948(US-Canada Toll Free)

Metastatic Prostate Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

Published By :

DelveInsight

Published Date : Aug 2014

Category :

Cancer

No. of Pages : N/A


The Report will be Dispatched in 3 Working days. 

DelveInsights, Metastatic Prostate Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. 

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope 

  • A snapshot of the global Market therapeutics scenario for  Metastatic Prostate Cancer.
  • A review of the marketed products under prescription for  Metastatic Prostate Cancer, regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges. 
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
  • Product profiles for marketed products for  Metastatic Prostate Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
  • Coverage of API Manufacturers for  Metastatic Prostate Cancer drugs in the United States, Europe and Asian Regions with location details.
  • Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for  Metastatic Prostate Cancer drugs.
  • Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with  Metastatic Prostate Cancer drugs.
  • Coverage of  Metastatic Prostate Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
  • Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
  • Key discontinued Marketed products.
  • Global Sales Figure from 2011-2015.

Reasons to buy 

  • Evaluate the marketing status and exclusivity details of  Metastatic Prostate Cancer key products to exploit opportunities for generic drug development opportunities.
  • Identify and understand important and diverse types of therapeutics under Phase III development for  Metastatic Prostate Cancer.
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to ‘Disease’.
  • API intelligence over marketed drugs for  Metastatic Prostate Cancer and gaining primary intelligence over active ingredients manufacturers across the globe.
  • API intelligence over leading Phase III pipeline drugs.
  • Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
  • Understanding the scope of the Phase III Drugs with nil regulatory filings.
  • Understanding the chemical route of synthesis of approved drugs for  Metastatic Prostate Cancer.
  • Uncovering opportunities in the rapidly growing the US markets.
Table of Content

Indication Overview


Marketed Drugs Assessment
Marketed Details of Drugs by Application Type
Marketed Details of Drugs (NDA) by Marketing Status
Marketed Details of Drugs by Patent Expiration Timeline
The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
The API Manufacturers by the United States Drug Master File (US DMF) Status
The API Manufacturers by the US DMF Status (Drug Specific)
The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
The API Manufacturers by the US DMF Status (Drug Specific)
Drugs Market Data and Forecasted Sales Figures (2011-2015)
Marketed Drugs Information
Drugs Description
Route of Synthesis
Global Active Pharmaceutical Manufacturers
Approval Status
Patent and Exclusivity Details
Company Overview
Phase III Drugs Information
Phase III Drugs Description
The United States Drug Master Filings (US DMF)
Discontinued Drugs Information

List of Table


Metastatic Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Metastatic Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Metastatic Prostate Cancer Therapeutic Market, US, (Year), 2014
Metastatic Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2014
Metastatic Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Metastatic Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Metastatic Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2014
Metastatic Prostate Cancer Marketed Drugs, API Manufacturers, Global, 2014
Metastatic Prostate Cancer Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Metastatic Prostate Cancer, 2014

List of Chart


Metastatic Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Metastatic Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Metastatic Prostate Cancer Therapeutic Market, US, (Year), 2014
Metastatic Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Metastatic Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Metastatic Prostate Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Metastatic Prostate Cancer Therapeutic Market, Global Sales (in million USD), 2014
Metastatic Prostate Cancer Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *